As part of GE Healthcare’s campaign to accelerate diagnosis and therapies for cancer, it has developed a new contrast agent designed for imaging angiogenesis called the F18 Angio radioactive PET. The new agent tracks the process of angiogenesis, the formation of new blood vessels in the body, which are formed during wound healing, but also as cancerous tumors recruit blood vessels to sustain accelerated growth. The theory is that a molecular imaging agent that binds to angiogenesis could help physicians locate tumors. Imaging the angiogenic process would then enable clinicians to monitor the effectiveness of anti-angiogenic cancer drugs and patient response to drug therapy.